Galmed Pharmaceuticals (NASDAQ:GLMD) will be issuing its quarterly earnings data before the market opens on Tuesday, March 13th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.
Shares of Galmed Pharmaceuticals (GLMD) opened at $6.38 on Monday. The company has a market cap of $96.27, a price-to-earnings ratio of -5.23 and a beta of 2.90. Galmed Pharmaceuticals has a 52-week low of $3.61 and a 52-week high of $12.22.
GLMD has been the topic of several recent analyst reports. Maxim Group set a $14.00 price objective on shares of Galmed Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, January 3rd. Zacks Investment Research raised shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.50 target price for the company in a research note on Tuesday, November 14th. ValuEngine cut shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Roth Capital began coverage on shares of Galmed Pharmaceuticals in a research note on Wednesday, November 15th. They set a “buy” rating and a $32.00 target price for the company. Finally, HC Wainwright raised their target price on shares of Galmed Pharmaceuticals from $18.00 to $24.00 and gave the company a “buy” rating in a research note on Monday, February 12th. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $20.40.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.